Howard Weintraub, MD
NYU Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation and treatment of patients prior to noncardiac surgery. He has also authored several articles on endothelial function and participated in clinical trials for treatment of lipid disorders. Dr. Weintraub has been named to the editorial board of Cardiology Review. He is one of the senior faculty in Vascular Biology Working Group and the Coalition for the Advancement of Cardiovascular Health, and is also a consultant to several pharmaceutical companies. (This is me - Update Profile)
| 2004 - present | Clinical Director NYU Medical Center |
|---|
GLG Study Groups with Howard Weintraub, MD(?)
| Study Group Name | Members |
|---|---|
| Non-Electrophysiologist Cardiologists (US) | 832 |
| Cardiologists Specializing in Lipids (US) | 162 |
| General Cardiologists (US) | 1333 |
| Physicians who Treat Hypertension (US) | 664 |
GLG NewsSM Analyses by Howard Weintraub, MD(?)
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in...
It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone...
GLG InstituteSM Seminars with Howard Weintraub, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Howard Weintraub, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

